Teriparatide treatment complicated by malignant myeloma

BMJ Case Reports

Volumn , Issue , 2010, Pages

  Koski, Anna Mari ^a   Sikiö, Anu ^a   Forslund, Terje ^a  

^a Central Finland Health Care District   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84897586354     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr.01.2010.2681     Document Type: Article

References (11)

1. Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26:688-703. [CrossRef] [Medline] [Web of Science] (Pubitemid 41127277)
2. Divieti P, Inomata N, Chapin K, et al. Receptors for the carboxyl-terminal region of pth(1-84) are highly expressed in osteocytic cells. Endocrinology 2001;142:916-25. [CrossRef] [Medline] [Web of Science] (Pubitemid 32222442)
3. Reeve J, Meunier PJ, Parsons JA, et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J 1980;280:1340-4. [Abstract/FREE Full text] (Pubitemid 10124272)
4. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41. [CrossRef] [Medline] [Web of Science] (Pubitemid 32402100)
5. Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002;30:312-21. [Abstract/FREE Full text] (Pubitemid 34556102)
6. Forslund T, Koski AM, Koistinen A, et al. Malignant myeloma in a patient after treatment for osteoporosis with teriparatide: a rare coincidence. Clin Med Case Rep 2008;1:119-22. Search Google Scholar
7. Ocqueteau M, Orfao A, Almeida J, et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 1998;152:1655-65. [Medline] [Web of Science] (Pubitemid 28275024)
8. Bladé J. Clinical practice. Monoclonal gammopathy of undetermined significance. N Engl J Med 2006;355:2765-70. [CrossRef] [Medline] (Pubitemid 46021514)
9. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354:1362-9. [CrossRef] [Medline] [Web of Science]
10. Buxton EC, Yao W, Lane NE. Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). J Clin Endocrinol Metab 2004;89:3332-6. [CrossRef] [Medline] (Pubitemid 38951900)
11. Beaudreuil J, Cohen-Solal M, Doré MX, et al. Secretion of parathyroid hormone-related peptide in patients with multiple myeloma. Rev Rhum Engl Ed 1996;63:502-3. [Medline] (Pubitemid 26318446)